Current strategies for patients with permanent end-organ damage related to PAD atheromatosis or with extensive aneurysmal symptomatology have focused on regulating KLF-4 expression, as the serum levels increase as a direct impact of the endothelial, smooth muscle, and immune cells. This evidence concerns the gene KLF4 and peripheral arterial disease.